ListarMD - Artículos por tema "Real-world data"
Mostrando ítems 1-1 de 1
-
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso
; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ...